| Literature DB >> 32572266 |
Pier Vitale Nuzzo1,2,3, Jacob E Berchuck1,2, Keegan Korthauer4,5, Sandor Spisak2, Amin H Nassar1,2, Sarah Abou Alaiwi1,2, Ankur Chakravarthy6, Shu Yi Shen6, Ziad Bakouny1, Francesco Boccardo3,7, John Steinharter1, Gabrielle Bouchard1, Catherine R Curran1, Wenting Pan1, Sylvan C Baca1,2,8, Ji-Heui Seo1,2, Gwo-Shu Mary Lee1,2, M Dror Michaelson9, Steven L Chang10, Sushrut S Waikar11,12, Guru Sonpavde1, Rafael A Irizarry13,14, Mark Pomerantz1,2, Daniel D De Carvalho6,15, Toni K Choueiri16,17, Matthew L Freedman18,19,20.
Abstract
Improving early cancer detection has the potential to substantially reduce cancer-related mortality. Cell-free methylated DNA immunoprecipitation and high-throughput sequencing (cfMeDIP-seq) is a highly sensitive assay capable of detecting early-stage tumors. We report accurate classification of patients across all stages of renal cell carcinoma (RCC) in plasma (area under the receiver operating characteristic (AUROC) curve of 0.99) and demonstrate the validity of this assay to identify patients with RCC using urine cell-free DNA (cfDNA; AUROC of 0.86).Entities:
Mesh：
Substances：
Year: 2020 PMID： 32572266 PMCID： PMC8288043 DOI： 10.1038/s41591-020-0933-1
Source DB: PubMed Journal: Nat Med ISSN： 1078-8956 Impact factor: 53.440